Menlo Park–based biomanufacturing company Antheia, founded in 2015 by Dr. Christina Smolke and Dr. Kristy Hawkins, announced a $56 million Series C funding round led by Global Health Investment Corporation (GHIC) and EDBI. The financing will support commercialization of its first biosynthetic product, thebaine—a key input in naloxone (Narcan)—and help advance additional candidates from its 70+ compound pipeline spanning neurology, oncology, gastrointestinal, respiratory, hematology, endocrinology, and anti-infectives. Several…
